| Dr Dennis Karl Chernin, MD, MPH | |
|
2345 S Huron Pkwy, Ann Arbor, MI 48104-5124 | |
| (734) 973-3030 | |
| (734) 973-3057 |
| Full Name | Dr Dennis Karl Chernin |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 49 Years |
| Location | 2345 S Huron Pkwy, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720177561 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 4301043276 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Mercy Hospital | Ann arbor, MI | Hospital |
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Entity Name | Dennis K Chernin Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013248012 PECOS PAC ID: 4284767153 Enrollment ID: O20100728001110 |
News Archive
Waiting a day or more to get lab results back from the doctor's office soon could become a thing of a past.
According to researchers patients given a mix of modern blood pressure drugs are one-third less likely to develop diabetes than those on older pills.
Researchers from Germany recently analyzed saliva and fecal samples from SARS-CoV-2 infected and post-COVID-19 patients and controls while considering multiple influencing factors during hospitalization. This study is available on the bioRxiv* preprint server.
A bioinformatics expert at the IRCM, Benjamin Haibe-Kains, recently published an article stressing the importance of standardizing drug screening studies in the prestigious scientific journal Nature. The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dennis Karl Chernin, MD, MPH 1700 Ives Ln, Ann Arbor, MI 48104-4501 Ph: (734) 662-2353 | Dr Dennis Karl Chernin, MD, MPH 2345 S Huron Pkwy, Ann Arbor, MI 48104-5124 Ph: (734) 973-3030 |
News Archive
Waiting a day or more to get lab results back from the doctor's office soon could become a thing of a past.
According to researchers patients given a mix of modern blood pressure drugs are one-third less likely to develop diabetes than those on older pills.
Researchers from Germany recently analyzed saliva and fecal samples from SARS-CoV-2 infected and post-COVID-19 patients and controls while considering multiple influencing factors during hospitalization. This study is available on the bioRxiv* preprint server.
A bioinformatics expert at the IRCM, Benjamin Haibe-Kains, recently published an article stressing the importance of standardizing drug screening studies in the prestigious scientific journal Nature. The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 6 days ago
Jeffrey Evans Terrell, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Arthur Oleinick, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 2016 Vinewood Blvd, Ann Arbor, MI 48104 Phone: 734-665-7693 | |
Joseph Valle, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 3131 S State St, Ann Arbor, MI 48108 Phone: 734-213-6285 Fax: 734-213-6482 | |
Matthew L Boulton, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1415 Washington Hts, Ann Arbor, MI 48109 Phone: 734-936-1623 | |
David Gulapa Paje, M.D. Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. James P Bagian, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 24 Frank Lloyd Wright Dr Lbby M, Ann Arbor, MI 48105 Phone: 734-930-5920 Fax: 734-930-5877 | |
Jennifer Marie Mcdonald, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 380 Parkland Plaza, Floor 1 Suite 110, Ann Arbor, MI 48103 Phone: 734-998-7380 |